TOKYO Oct 8 (Reuters) - Data for a Roche Holding AG (ROG.VX) breast cancer drug and a lung cancer drug set to be presented at a European oncology conference that starts later in the day was "stunning", the Swiss drugmaker's chief executive said on Friday.
